Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
Jump to

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Diabetes mellitus increases the incidence of recurrent heart failure through a variety of potential mechanisms, including ischemic myocardial damage, hyperglycemia, and the effects of the glucose-linked metabolic abnormalities on the myocardium.1 To date, randomized controlled trials of more versus less glucose lowering with a menu of drugs, including insulin, have reported a neutral effect on incident heart failure. Nevertheless, epidemiological studies and the sodium-retaining properties of insulin have fueled concerns about a possible link.2
The ORIGIN trial (Outcome Reduction With Initial Glargine Intervention) allocated 12 537 people (mean age, 64 years; 35% women) with diabetes mellitus (88%), impaired glucose tolerance, or impaired fasting glucose to either basal insulin-mediated normoglycemia or therapy without insulin and reported a neutral effect on cardiovascular events during a median follow-up of 6.2 years. People with New York Heart Association class 3 or 4 heart failure were excluded. Heart failure requiring hospitalization was a prespecified component of the primary outcome and was defined as evidence of overnight hospitalization or attendance in an acute care setting for at least 2 of the following: signs or symptoms of heart failure; radiological evidence of congestive heart failure; treated with intravenous diuretics, or a first or increased dose of an oral diuretic, intravenous or oral vasodilator, or intravenous or oral inotrope.3 Both first and recurrent episodes were prospectively collected and …
American Heart Association Professional?
Log in using your username and password
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
This Issue
Jump to
Article Tools
- Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure HospitalizationHertzel C. Gerstein, Hyejung Jung, Lars Rydén, Rafael Diaz, Richard E. Gilbert and Salim Yusuf On behalf of the ORIGIN InvestigatorsCirculation. 2018;137:88-90, originally published December 26, 2017https://doi.org/10.1161/CIRCULATIONAHA.117.030924
Citation Manager Formats
Share this Article
- Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure HospitalizationHertzel C. Gerstein, Hyejung Jung, Lars Rydén, Rafael Diaz, Richard E. Gilbert and Salim Yusuf On behalf of the ORIGIN InvestigatorsCirculation. 2018;137:88-90, originally published December 26, 2017https://doi.org/10.1161/CIRCULATIONAHA.117.030924